Related Experiment Video
Updated: Jun 25, 2026
Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
Published on: February 17, 2016
Effect of cell differentiation for neuroblastoma by vitamin k analogs
Toshimitsu Nakayama1, Satoru Asami, Shin-Ichi Ono
1College of Pharmacy, Nihon University, Chiba, Japan.
Background:
Lack of receptor tyrosine kinase (TrkA), a high-affinity nerve growth factor (NGF) receptor, is closely associated with the malignant progression of neuroblastoma (NB) and its prognosis. Vitamin K3 (VK3) analogs inhibit the activity of protein tyrosine phosphatases (PTPases), which causes hydrolysis of the phosphate groups bound to the tyrosine residues on tyrosine kinase, resulting in sustained tyrosine phosphorylation.
Methods:
In order to reverse this abnormal NGF/TrkA signal transduction in NB cells, we synthesized new VK3 analogs and examined their activity against NB cells.
Results:
VK3 analogs increased or maintained the expression level of c-fos mRNA in the NB cells, which express the downstream genes of NGF/TrkA signal transduction. Moreover, the expression level of GAP-43 mRNA, which is a marker of neurite outgrowth and neuronal differentiation, was increased and morphological differentiation was also observed. VK3 analogs (especially COOH analog) continued to express c-fos and GAP-43 mRNAs and induced differentiation of NB cells after stimulation of NGF by strong inhibition of PTPase without affecting TrkA autophosphorylation.
Conclusions:
Vitamin K3 analogs may have potential as clinical therapeutic agents for NB.
Insights
New Vitamin K3 (VK3) analogs show promise for treating neuroblastoma (NB). These compounds reverse abnormal nerve growth factor (NGF) signaling by inhibiting phosphatases, promoting NB cell differentiation and potentially improving prognosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Neuroblastoma (NB) malignancy and prognosis are linked to reduced neurotrophin receptor TrkA activity.
- Vitamin K3 (VK3) analogs are known inhibitors of protein tyrosine phosphatases (PTPases).
Purpose of the Study:
- To investigate the therapeutic potential of novel VK3 analogs in reversing aberrant NGF/TrkA signaling in NB cells.
- To evaluate the effects of VK3 analogs on NB cell differentiation and gene expression.
Main Methods:
- Synthesis of new Vitamin K3 (VK3) analogs.
- Treatment of neuroblastoma (NB) cells with VK3 analogs.
- Analysis of c-fos and GAP-43 mRNA expression levels.
- Assessment of morphological differentiation.
Main Results:
- VK3 analogs maintained or increased c-fos mRNA expression, a downstream target of NGF/TrkA signaling.
- VK3 analogs significantly increased GAP-43 mRNA expression and induced morphological differentiation in NB cells.
- The COOH analog demonstrated sustained c-fos and GAP-43 mRNA expression and induced differentiation by inhibiting PTPase activity without impacting TrkA autophosphorylation.
Conclusions:
- Vitamin K3 (VK3) analogs show potential as therapeutic agents for neuroblastoma (NB).
- VK3 analogs may offer a novel strategy to reverse aberrant NGF/TrkA signaling and promote neuronal differentiation in NB.
More Related Videos
07:48Three-Dimensional In Vitro Biomimetic Model of Neuroblastoma Using Collagen-Based Scaffolds
Published on: July 9, 2021
08:23Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
Published on: August 9, 2014